Clinical trial · Interventional
Axumin PETMRI Imaging Following Focal Cryo-ablation (FCA)
CLINICAL UTILITY OF AXUMIN PET/MRI IMAGING TWO YEARS FOLLOWING FOCAL CRYO-ABLATION (FCA) OF PROSTATE CANCER
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective outcomes study assessing quality of life and oncological control at pre-defined time points following FOCAL CRYO-ABLATION (FCA). The investigator's standard of care is to perform an Magentic Resonance Imaging (MRI) and prostate biopsy two years following FCA. The prostate biopsy assesses both the presence of in field and out of field disease. The role of Axumin PET/MRI for detecting disease following FCA has not been previously examined.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fluciclovine PET scan added to MRI | Other | — | UNRESOLVED |
| Standard of Care MRI | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Standard of Care
- interventionNames
- Device: Standard of Care MRI
- type
- EXPERIMENTAL
- label
- 18F-Fluciclovine PET Scan
- interventionNames
- Other: Fluciclovine PET scan added to MRI
Primary outcomes (1)
- measure
- Measure of sensitivity following PET imaging with 18-F fluciclovine (Axumin)
- timeFrame
- 1 Day
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * FCA at NYU Langone Health performed at least two years prior to study enrollment by Drs. Lepor or Wysock. * No prostate cancer specific treatment following FCA * Consented to undergo reflex MRI and prostate biopsy two years following FCA. Exclusion Criteria: * Any contraindication to prostate biopsy * Prior allergic reaction to 18F-Fluciclovine * Patient refuses MRI and prostate biopsy two years following FCA.
References
Publications (0)
Data not yet available